This small-cap stock surged 75% since IPO price but ICICI Securities sets target below CMP; what should shareholders do?

Sudeep Pharma shares have surged nearly 75% from their initial public offering (IPO) price of ₹593 in less than a year, reflecting strong investor interest in the pharmaceutical company and its growth prospects. The stock made a robust debut on 28 November, listing at ₹730 per share on the NSE, a premium of 23.10% over its issue price. On the BSE, it debuted at ₹733.95, marking a 23.77% premium.

However, ICICI Securities believes the stock’s valuation has run ahead of its fundamentals, despite the company’s promising position in the battery materials segment. The brokerage has maintained its Hold rating on Sudeep Pharma while raising its target price to ₹1,000 from ₹700, based on its 13 October assessment. The revised target remains below the closing market price of ₹1,018 on 13 October.

ICICI Securities said Sudeep Pharma is uniquely positioned in India’s battery materials market as the country’s sole producer of iron phosphate. Its proprietary green technology gives it an advantage over domestic peers, while its product has already received approval from eight customers ahead of the commercialisation of its first-phase facility.

The company’s 25,000-tonne-per-annum (TPA) facility is expected to become operational in early FY28. Sudeep Pharma plans to expand capacity to 100,000–200,000 TPA by FY31 to cater to an estimated 100–200 gigawatt-hours (GWh) of lithium iron phosphate (LFP) battery capacity.

The brokerage’s confidence in the company’s execution is supported by its existing food-grade iron phosphate business, which has more than a decade of manufacturing experience.

Despite the growth opportunity, ICICI Securities cautioned that Sudeep Pharma’s valuation already reflects significant expectations for its nascent battery chemicals business.

The brokerage expects EBITDA from the company’s core business to rise to ₹3.3 billion by FY29, implying a compound annual growth rate (CAGR) of 15% over FY26–FY29. Applying an enterprise value (EV)-to-EBITDA multiple of 25 times to the core business yields an estimated enterprise value of ₹84 billion.

At the 13 October market price of ₹1,018, Sudeep Pharma’s total consolidated enterprise value stood at ₹119 billion. This implies that the market is assigning a residual enterprise value of ₹36 billion to its iron phosphate business, according to the brokerage.

Based on its estimated iron phosphate segment EBITDA of ₹0.9 billion in FY29 and ₹2.3 billion in FY30, ICICI Securities said the market is valuing the battery chemicals business at an aggressive 39 times FY29 EBITDA and 16 times FY30 EBITDA. These valuations, it noted, leave limited room for execution setbacks.

The brokerage has marginally revised its FY27 and FY28 estimates and introduced FY29 projections. Rolling forward its valuation to FY29 and retaining its target price-to-earnings multiple of 40 times has led to the revised target price of ₹1,000. Despite the increase in its target, ICICI Securities has retained its Hold recommendation.

ICICI Securities highlighted Sudeep Pharma’s proprietary, ammonia-free production technology as a key differentiator in a market dominated by Chinese manufacturers.

China has a strong cost advantage in iron phosphate production, supported by an established battery materials ecosystem and the use of ferrous sulphate, a low-cost byproduct of titanium dioxide manufacturing through the ammonia process. However, the brokerage noted that this route generates substantial wastewater and creates challenges related to byproduct disposal.

Sudeep Advance Materials, a wholly owned subsidiary of Sudeep Pharma, uses a different iron source and a proprietary production process that does not rely on ammonia. According to ICICI Securities, this approach significantly reduces effluent generation and offers a greener, potentially more scalable alternative to conventional manufacturing methods.

While this technology and the planned capacity expansion offer long-term opportunities, the brokerage believes the current valuation already reflects substantial optimism around the battery chemicals business. It therefore recommends a Hold rating, with a target price of ₹1,000 per share.

Dhanya Nagasundaram works as a Content Producer at LiveMint, specializing in news related to financial markets, stocks, and business. With over eight years of experience in journalism and content creation, she has honed her skills in data-driven reporting and market analysis. Her focus is on monitoring stock trends, initial public offerings (IPOs), corporate news, policy shifts, and larger economic trends that affect investors and market players. <br><br> At LiveMint, Dhanya consistently writes and produces articles that make complex financial topics accessible to readers. She keeps a close eye on equity markets, commodities, and macroeconomic indicators, assisting audiences in comprehending how global and domestic events influence investment perspectives. Her stories frequently underscore emerging trends within sectors, the IPO market, company earnings results, and market strategies pertinent to both retail and institutional investors. <br><br> Before her tenure at LiveMint, Dhanya accumulated a wealth of professional experience at various companies, including MintGenie, Informist, Cogenics, Chary Publications, KPMG, and the Royal Bank of Scotland. These positions allowed her to establish a solid foundation in financial research, reporting, and content creation. <br><br> Throughout her career, she has explored numerous subjects such as trading strategies, commodities, IPOs, wealth generation, corporate profits, and macroeconomic indicators. Her background in both financial journalism and corporate settings has given her the ability to tackle stories with analytical rigor while ensuring clarity for her audience. Through her contributions, Dhanya strives to deliver insightful, trustworthy, and investor-centric financial content.

Get Latest real-time updates

Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

HomeMarketsStock MarketsThis small-cap stock surged 75% since IPO price but ICICI Securities sets target below CMP; what should shareholders do?

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.